/ /

  • linkedin
  • Increase Font
  • Sharebar

    Promising results for keratitis treatment with use of CXL, riboflavin

    Small study supports what other researchers have found for combined, solo therapy


    Infectious keratitis is a potentially blinding disease, and some cases are challenging to treat, said Ashraf H. El Habbak, MD, PhD.

    Although most cases are bacterial and resolve with topical broad-spectrum antibiotics, emerging antibiotic-resistant ulcers remain a threat, said Dr. El Habbak, professor, Department of Ophthalmology, Benha University, Egypt.

    This has led to increased interest in the use of corneal crosslinking (CXL) to treat infectious keratitis, Dr. El Habbak said.

    Corneal crosslinking is already used for keratoconus and other forms of corneal ectasia.

    “Ultraviolet rays and topical riboflavin change the physiochemical properties of corneal collagen and by increasing its stiffness,” he said. “These changes increase the collagen resistance to the bacterial degradation enzymes.”

    There are in vitro studies that address the efficacy of riboflavin and ultraviolet CXL against various pathogens, including methicillin-resistant Staphyloccocus aureus, multi drug-resistant Pseudomonas, and drug-resistant Streptococcus pneumoniae.

    “However, clinical reports proving the efficacy of riboflavin UV/crosslinking in the treatment of microbial keratitis and arresting the corneal melts are still limited,” Dr. El Habbak said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results